#REPL↓

REPL/ 10/20/2025 · 9:46 AM

Replimune Gets FDA Nod for RP1 Drug Resubmission

Replimune's RP1 melanoma treatment gets FDA acceptance for BLA resubmission with April 2026 review date. Wedbush upgrades stock to Outperform with $18 target as approval odds improve.

REPL/ 09/19/2025 · 7:03 AM

JPMorgan Downgrades Replimune Due to Regulatory Uncertainty

Replimune’s cancer drug, RP1, hit a snag after an FDA meeting. Quick approval is now unlikely due to regulatory uncertainty, causing the stock to drop sharply (39% Thursday). The company is seeking a new way forward for the melanoma treatment.